SCHEMBL3597353

SCHEMBL3597353

BrCCCCCc1ccco1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.59
TDP1 Q9NUW8 2/20 0.59
CYP3A4 P08684 1/20 0.59
ALOX15 P16050 1/20 0.59
USP2 O75604 1/20 0.59
HPGD P15428 1/20 0.59
CHRM2 P08172 1/20 0.44
EPHX2 P34913 3/20 0.39
KCNH3 Q9ULD8 1/20 0.38
GLS O94925 1/20 0.37
THRA P10827 1/20 0.35
THRB P10828 1/20 0.35
MAPK1 P28482 1/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
ALOX5 P09917 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10558471 1.00 ALDH1A1 (0.59) ALDH1A1TDP1CYP3A4ALOX15USP2
SCHEMBL9390772 1.00 ALDH1A1 (0.59) ALDH1A1TDP1CYP3A4ALOX15USP2
SCHEMBL11362865 0.98 ALDH1A1 (0.56) ALDH1A1TDP1CYP3A4ALOX15USP2
SCHEMBL5355893 0.91
SCHEMBL9509561 0.89 ALDH1A1 (0.50) ALDH1A1TDP1CYP3A4ALOX15USP2
SCHEMBL9508696 0.89 ALDH1A1 (0.50) ALDH1A1TDP1CYP3A4ALOX15USP2
SCHEMBL7093157 0.89 ALDH1A1 (0.70) ALDH1A1TDP1CYP3A4ALOX15USP2
SCHEMBL7094868 0.87 ALDH1A1 (0.67) ALDH1A1TDP1CYP3A4ALOX15USP2
SCHEMBL9509614 0.86 ALDH1A1 (0.46) ALDH1A1TDP1CYP3A4ALOX15USP2
SCHEMBL5326204 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674825-B2 Dicarboxylic acid derivatives with pharmaceutical properties BAYER AKTIENGESELLSCHAFT (DE) 2010-03-09 US disclosed
US-20080058314-A1 Novel dicarboxylic acid derivatives with pharmaceutical properties BAYER AKTIENGESELLSCHAFT 2008-03-06 US disclosed
EP-0207453-B1 Heterocyclic substituted-phenoxyalkyl-isoxazoles and-furans, their preparation and use as antiviral agents STERLING WINTHROP INC (US) 1994-06-22 EP disclosed
EP-0207454-B1 ISOXAZOLE AND FURAN DERIVATIVES, THEIR PREPARATION AND USE AS ANTIVIRAL AGENTS STERLING WINTHROP INC. (US) 1992-09-09 EP disclosed
US-5104885-A 5-(phenylalkoxy)primaquine and 5[(heterocycle)alkoxy] primaquine compounds and their use for treatment of malaria CALSPAN CORPORATION (US) 1992-04-14 US disclosed
US-5101372-A Optimum performance standard cell array multiplier INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 1992-03-31 US disclosed
US-4861791-A Dihydro-oxazolyl substituted-phenyl-aliphatic lower alkyl and their use as antiviral agents STERLING DRUG INC. (US) 1989-08-29 US disclosed
US-4857539-A Heterocyclic substituted-phenoxyalkylisoxazoles as antiviral useful agents STERLING DRUG INC. (US) 1989-08-15 US disclosed
EP-0207454-A2 Isoxazole and furan derivatives, their preparation and use as antiviral agents STERLING WINTHROP INC. (US) 1987-01-07 EP disclosed
EP-0207453-A2 Heterocyclic substituted-phenoxyalkyl-isoxazoles and-furans, their preparation and use as antiviral agents STERLING WINTHROP INC. (US) 1987-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058314-A1 Novel dicarboxylic acid derivatives with pharmaceutical properties PC, GOT2, SDHA ALDH1A1 302/4885TDP1 2697/4885CYP3A4 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.